Kevin Jorge Magaño Bocanegra

Mr. Kevin Jorge Magaño Bocanegra

Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EBELAYNE IRENE BECERRA BAEZ
ELAYNE IRENE BECERRA BAEZ
STSergio Enrique Meza Toledo
Sergio Enrique Meza Toledo
PMPaola Muñoz-Lopez
Paola Muñoz-Lopez
LFLuis Fernando Flores-Martínez
Luis Fernando Flores-Martínez
KFKarla Fraga-Pérez
Karla Fraga-Pérez
RLRosendo Luria-Pérez
Rosendo Luria-Pérez
Over a century ago, bacterial extracts were found to be useful in cancer therapy, but this treatment modality was obviated for decades. Currently, in spite of the development and advances in chemotherapies and radiotherapy, failure of these conventional treatments still represents a major issue in the complete eradication of tumor cells and has led to renewed approaches with bacteria-based tumor therapy as an alternative treatment. In this context, live-attenuated bacteria, particularly Salmonella enterica, have demonstrated tumor selectivity, intrinsic oncolytic activity, and the ability to induce innate or specific antitumor immune responses. Moreover, Salmonella enterica also has strong potential as a delivery system of tumor-associated antigens, cytotoxic molecules, immunomodulatory molecules, pro-apoptotic proteins, and nucleic acids into eukaryotic cells, in a process known as bactofection and antitumor nanoparticles. In this review, we present the state of the art of current preclinical and clinical research on the use of Salmonella enterica as a potential therapeutic ally in the war against cancer.

26 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlvaro De Jesus Huamani Ortiz
Alvaro De Jesus Huamani Ortiz
Anthony Vladimir Campos SeguraAnthony Vladimir Campos Segura
Anthony Vladimir Campos Segura
KBKevin Jorge Magaño Bocanegra
Kevin Jorge Magaño Bocanegra
MSMariana Belén Velásquez Sotomayor
Mariana Belén Velásquez Sotomayor
HPHELI JAIME BARRON PASTOR
HELI JAIME BARRON PASTOR
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
Background/Objectives: Gastric cancer (GC) is a highly aggressive malignancy with diverse molecular subtypes. While microsatellite instability (MSI) GC generally carries a favorable prognosis, a subset of patients experiences poor outcomes, highlighting the need for refined prognostic markers. Methods: This study utilized transcriptomic and clinical data from two independent cohorts, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG), to identify novel prognostic genes in MSI-GC. Results: Through rigorous survival analysis, we identified high MAP4K4 expression (MAP4K4high) as an independent and robust predictor of poor overall survival (OS) and disease-free survival (DFS) specifically within the MSI-GC subtype. MAP4K4high was associated with increased hazard ratios for both OS and DFS in both cohorts, even after adjusting for clinicopathological factors. Further analysis revealed that MAP4K4high MSI-GC tumors exhibit a distinct molecular profile characterized by increased extracellular matrix remodeling, epithelial–mesenchymal transition, and a microenvironment enriched in monocytes and cancer-associated fibroblasts (CAFs). Notably, a subgroup of MSI-GC patients with a CIN-like phenotype and high MAP4K4 expression exhibited particularly dismal outcomes. Conclusions: Our findings establish MAP4K4 as a promising prognostic biomarker for risk stratification in MSI-GC and suggest its potential role in driving aggressive tumor behavior through modulation of the tumor microenvironment.